new BindingDB logo
myBDB logout

27 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28274635 381 Identification of novel TACE inhibitors compatible with topical application.EBI Nestl� Skin Health R&D
26871660 68 Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.EBI San Raffaele Scientific Institute
26192023 71 SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.EBI £Florida Atlantic University
24044434 71 Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.EBI Università di Pisa
19715320 87 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI University of Florida
19635666 119 Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.EBI Incyte Corporation
20638281 56 Structure and activity relationships of tartrate-based TACE inhibitors.EBI Merck Research Laboratories
21458257 87 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.EBI Merck Research Laboratories
21106451 39 Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.EBI Merck Research Laboratories
20180536 128 Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.EBI Universit£ di Pisa
20172725 49 Discovery and SAR of hydantoin TACE inhibitors.EBI Merck Research Laboratories
20022498 71 The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.EBI Schering-Plough Research Institute Cambridge
18835710 69 Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.EBI Schering Plough Research Institute
19457660 90 Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.EBI Incyte Corporation
18790648 317 Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI University of Athens
18068976 132 Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.EBI Incyte Corporation
18036818 157 Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.EBI Incyte Corporation
17256836 84 Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.EBI Incyte Corporation
15546732 11 Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors.EBI Department of Life Science and National Research Laboratory of Proteolysis
28558971 38 Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors.EBI Merck& Co.
28408220 55 First insight into structure-activity relationships of selective meprin? inhibitors.EBI Fraunhofer Institute for Cell Therapy and Immunology IZI
22299577 12 Three new aromatic sulfonamide inhibitors of carbonic anhydrases I, II, IV and XII.BDB UniversitÓ di Firenze